Chemotherapy is the first line treatment for many cancers; however, it is rarely curative. Despite wide clinical use, it is unclear what distinguishes responders from non-responders and the factors that drive a robust anti-cancer response. This has hindered the identification of predictive biomarkers that can guide clinical decision making as well as the development of new combination treatment strategies. Here, we characterised the tumor microenvironment associated with a complete response to cyclophosphamide chemotherapy; demonstrated that tumors can be sensitised to chemotherapy by inducing a chemo-sensitive phenotype; and investigated the relationship between cyclophosphamide effectiveness and T regulatory cells.
|Qualification||Doctor of Philosophy|
|Award date||11 Nov 2021|
|Publication status||Unpublished - 2021|